ST-905

ST-905 is an investigational small molecule dual agonist of the M1 and M4 muscarinic acetylcholine receptors, currently in Phase 1 clinical development by Syremis Therapeutics. The drug is being developed for the treatment of schizophrenia and other serious neuropsychiatric conditions. By targeting the M4 receptor, ST-905 aims to provide antipsychotic effects through the modulation of dopaminergic signaling in the striatum, while its activity at the M1 receptor is intended to improve cognitive symptoms associated with these disorders. This dual-mechanism approach represents a shift away from traditional dopamine D2 receptor antagonism, potentially offering a therapeutic option with a reduced burden of metabolic and motor side effects.